Program
trilaciclib
Also written as “Trilaciclib” and “Trilaciclib, carboplatin, etoposide,or Topotecan”.
Its studies are mostly in Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageTrilaciclib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharmacosmosits history only | 112 open or running | phase 4since Apr 12, 2023 | Jul 8, 2015 | Oct 31, 2027phase 3 · NCT07473128 |
| Simcere Pharmaceutical Group | 31 open or running | phase 4since Sep 28, 2021 | May 8, 2021 | Jul 15, 2027phase 3 · NCT07881705 |
Also a collaborator on its studies: Roche-Genentech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Simcere Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named trilaciclibINNProposed as its International Nonproprietary Name in WHO's List 117
- May 8, 2021First study: phase 3 study in Small Cell Lung CarcinomaFirst studyNCT04902885 · 95 enrolled · China
- Sep 28, 2021Phase 4 study in Small Cell Lung CarcinomaNCT05071703 · 30 enrolled · China
- Oct 12, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07881705 · 106 enrolled · China
Ahead
- Jul 15, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07881705
TargetBeta
“A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
Studies
All 3 Simcere Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07881705Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | Jul 15, 2027 | 106 |
| NCT05071703Small Cell Lung Carcinoma · China | 4 | Completed | Apr 10, 2022 | 30 |
| NCT04902885Small Cell Lung Carcinoma · China | 3 | Completed | Dec 29, 2021 | 95 |
How it is read
Names in the registry
- “Trilaciclib”, 13 entries
- “Trilaciclib, carboplatin, etoposide,or Topotecan”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 8 studies
- Triple Negative Breast Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.